Polyethylene glycol augments thyroid cAMP responses by fragments from protease-digested TSAb or TSBAb-IgG

Increased receptor binding by bovine (b) TSH bound to monoclonal antibody to bTSHbeta-subunit

TSH receptor (R) binding and cAMP production by bovine (b) TSH-bound to a monoclonal antibody (MoAb) or polyclonal antibody (Ab) to bTSH were examined, using TSH receptor (R) coating tube and porcine thyroid cells. (125) I-bTSH bound-to MoAbs to bTSH(alpha) or discontinuous type MoAb showed TSHR binding (10%) similar to intact (125) I-bTSH. TSHR binding was completely decreased (<2%) when (125) I-bTSH was bound by polyclonal Abs to bTSH(alpha) in Graves' patient or rabbit polyclonal Abs to bTSH. When either of the two MoAb (No. 1 and 2) to bTSH(beta) was bound to (125) I-bTSH, TSHR binding was 4 times higher (40%) compared to intact (125) I-bTSH. Binding of another MoAb (No. 3) caused no increased binding. TSHR binding of intact (125) I-bTSH was decreased from 10% to 2% by excess amounts of bTSH. Binding of (125) I-bTSH bound to MoAb to bTSH(beta) (No. 1 and 2) decreased from 40% to 30% by excess amounts of bTSH. When (125) I-bTSH bound-Fab of MoAb was used, the binding was reduced from 30 to 10% (No. 1) and from 25 to 6% (No. 2), respectively. In contrast, cAMP production by bTSH was decreased by pre-binding of all MoAbs and polyclonal Abs. Binding of (125) I-MoAb to bTSH (beta) to a synthetic peptide array of bTSH (beta) sequence was examined by the radioautography. The epitope of MoAb to bTSH(beta) was suggested to be LPK (beta 42-44) for No. 1, KLF (beta 39-41) for No. 2 and PKYA (beta 43-46) for No. 3, respectively, although the existence of discontinuous epitope could not be ruled out. The increased TSHR binding and the decreased cAMP production by bTSH bound to MoAbs may be due to the conformational change of TSH molecule or TSHR by binding of both bTSH and MoAb.

Antibody to immunoglobulin G and polyethylene glycol augment cyclic adenosine monophosphate production by TSH receptor antibody bound to porcine thyroid cells

Anti-immunoglobulin G (IgG) augments cyclic adenosine monophosphate (cAMP) production by thyroid-blocking antibody (TBAb) bound to porcine thyroid cells (PTC). This is described as a conversion phenomenon. We reported the effect of polyethylene glycol (PEG) to augment thyroid-stimulating antibody (TSAb) activity in a PTC assay. In the present experiment we examined the effect of anti-immunoglobulin G (IgG) and PEG on cAMP production from TBAb or TSAb bound to PTC. TBAb bound to PTC was separated from unbound TBAb by centrifugation after a first incubation (0.5 hour at 37 degrees C) of TBAb-IgG with PTC. TBAb bound to PTC were incubated with anti-human (h)IgG or hIgG fragments [F(ab')(2), Fc, Fd, H chain or L-chain] for 4 hours at 37 degrees C in the second incubation. Anti-IgG or anti-IgG fragments increased cAMP production. No conversion was caused by protein A, protein L, or PEG (5%). PEG did not augment cAMP production by these IgG antibodies. PEG augmented cAMP production during incubation of TSAb-IgG bound to PTC, but anti-IgG did not. PEG significantly augmented cAMP production by coincubation of TSAb-IgG bound to PTC and the unbound TSAb-IgG (obtained from the first incubation). A similar augmentative effect of PEG was also observed in experiments using TSAb-F(ab')(2) and TSAb-Fab. cAMP production by PTC bound by both TBAb- and TSAb-IgG was increased by co-incubation with anti-IgG, but was not increased by PEG. In conclusion, anti-IgG specifically increased cAMP production from TBAb bound to PTC (conversion phenomenon) and PEG specifically increased cAMP production by TSAb bound to PTC. Different mechanisms enhance cAMP production by TSAb and conversion of TBAb.

Antithyrotropin receptor antibody: an update

Numerous studies have reported the characteristics and significance concerning antithyrotropin receptor antibodies (TSHR-Abs), which cause Graves' disease and in some cases primary hypothyroidism. However, many unsolved questions concerning those antibodies remain. Here, recent developments in the study of TSHR-Abs are reviewed based on three aspects: mechanisms of TSHR-Ab production, antibody binding epitopes, and clinical TSHR-Ab assays. Mechanisms of TSHR-Ab production are discussed from five points of view: aberrant expression of the major histocompatibility complex, dysregulation of T cells, molecular mimicry, bystander effect, and expansion of autoreactive B cells. Regarding epitopes, unique TSHR-Abs have been reported that may explain the complicated pathophysiology of patients with TSHR-Ab diseases. Finally, recent efforts to improve TSHR-Ab measurements are introduced. Such efforts will contribute to clinical examinations and treatments for thyroid diseases as well as experimental methods of thyroidology.